Condition: Mesothelin-Expressing Tumors · Epithelial Ovarian Cancer · Malignant Pleural Mesothelioma, Advanced · Sponsor: Context Therapeutics Inc.
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.
This description comes directly from the study's public registry record.
Context Clinical Development · 267-225-7416 · cntx-ct95-101@contexttherapeutics.com
Always discuss trial participation with your own doctor first.
| Context Investigational Site | Denver, Colorado, United States | Recruiting |
| Context Investigational Site | Chicago, Illinois, United States | Recruiting |
| Context Investigational Site | Grand Rapids, Michigan, United States | Recruiting |
| Context Investigational Site | Hackensack, New Jersey, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Context Investigational Site | Philadelphia, Pennsylvania, United States | Recruiting |
| Context Investigational Site | Nashville, Tennessee, United States | Recruiting |
| Context Investigational Site | San Antonio, Texas, United States | Recruiting |
| Context Investigational Site | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06756035